Abbott Initiates Trial of Next-Generation XIENCE Primary Drug Eluting Stent Abbott has announced the initiation of SPIRIT PRIME, a clinical trial to study the performance of the company’s next-generation XIENCE Primary Everolimus Eluting Coronary Stent Program, currently an investigational device, for the treatment of coronary artery disease. Outcomes from SPIRIT PRIME will be used to aid the regulatory filing for XIENCE Primary in the usa Deltasone Oral . The first patient was enrolled in to the SPIRIT PRIME clinical trial at Hillcrest INFIRMARY in Tulsa, Okla., by Rajesh Chandwaney, M.D.
Abbott’s inclusion on the Operating Mom list for days gone by decade is a testament to our longstanding commitment to connecting people who have their potential, helping them to succeed and build extraordinary careers, said Stephen Fussell, senior vice president, RECRUITING, Abbott. We also continue steadily to concentrate on creating and applying innovative, targeted programs that meet up with the evolving desires of our employees, their families and our developing business around the global world. Abbott provides a comprehensive offering of healthcare, wellness, work/lifestyle and other family-friendly benefits, as well as flexible work options such as work sharing, compressed work-weeks, telecommuting and flextime to help employees find success at work and home.